Eric Venker - 01 Jul 2026 Form 4 Insider Report for Immunovant, Inc. (IMVT)

Reporting relationship: Chief Executive Officer, Director
Issuer ticker: IMVT
Reported as of: 01 Jul 2026
Net transaction value: -$118,980
SEC form: 4
Accepted by SEC: 06 Jul 2026, 17:01:25 UTC
Prior SEC filing: 26 Jun 2026
Next SEC filing: 29 Jul 2026
Source filing: View source filing
Reporting owner signature: /s/ Tiago Girao, Attorney-in-Fact for Eric Venker

Key filing fact

Eric Venker filed Form 4 for Immunovant, Inc. (IMVT) on 06 Jul 2026.

Key facts

This page summarizes Eric Venker's Form 4 filing for Immunovant, Inc. (IMVT).
4 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 06 Jul 2026, 17:01.

Change

Previous filing in this sequence was filed on 26 Jun 2026.
Current net transaction value: -$118,980.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001801917 Primary reporting owner

Venker Eric

Relationship: Chief Executive Officer, Director
Address: C/O IMMUNOVANT, INC., 1000 PARK FORTY PLAZA, SUITE 210, DURHAM
Signature: /s/ Tiago Girao, Attorney-in-Fact for Eric Venker
Signature date: 06 Jul 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

IMVT transaction

Common Stock

Options Exercise

Transaction value
Shares: +92,188
Change %: +37%
Price: $14.46^*
Shares after: 344,001
Date: 01 Jul 2026
Ownership: Direct
Footnotes: F1, F2

IMVT transaction

Common Stock

Disposed to Issuer

Transaction value
Shares: -86,629
Change %: -25%
Price: $38.14^*
Shares after: 257,372
Date: 01 Jul 2026
Ownership: Direct
Footnotes: F1, F2

IMVT transaction

Common Stock

Sale

Transaction value: $118,980
Shares: -3,092
Change %: -1.2%
Price: $38.48
Shares after: 254,280
Date: 02 Jul 2026
Ownership: Direct
Footnotes: F3

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

IMVT transaction Derivative

Capped Value Appreciation Rights

Options Exercise

Transaction value
Shares: -92,188
Change %: -8.3%
Price: $0.000000^*
Shares after: 1,014,062
Date: 01 Jul 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 92,188
Exercise price: $14.46
Footnotes: F1, F2, F4

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 4 footnotes

Footnote F1

On July 28, 2025, the Reporting Person was granted capped value appreciation rights ("CVARs"), as previously reported in a Form 4 filed on July 30, 2025, that entitle the Reporting Person to receive a payment equal to the product of (i) the number of vested CVARs multiplied by (ii) the excess (if any) of (A) the fair market value of the Issuer's common stock (capped at $16.76 per share) as of the relevant date of determination over (B) the applicable hurdle price of $14.46 (the "CVAR Amount"). The CVARs will then settle into a number of shares of common stock of the Issuer determined by dividing (i) the CVAR Amount by (ii) the fair market value of the Issuer's common stock as of such date.

Footnote F2

On July 1, 2026, the Service Requirement (as defined in Footnote 4), Performance Requirement (as defined in Footnote 4), Knock-In Requirement (as defined in Footnote 4), and hurdle price applicable to 92,188 vested CVARs were satisfied and, accordingly, the CVARs were settled into shares of the Issuer's common stock, determined by dividing (i) the CVAR Amount by (ii) the closing price of a share of the Issuer's common stock on July 1, 2026.

Footnote F3

The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these CVARs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.

Footnote F4

These CVARs vest on the first date that each of (i) the Service Requirement, (ii) the Performance Requirement, and (iii) the Knock-in Requirement have been satisfied. The "Service Requirement" is satisfied as follows: (i) 25% of the CVARs vested on April 1, 2026; and (ii) the remaining 75% vests in twelve (12) equal quarterly installments thereafter, subject to the Reporting Person's continuous service to the Issuer or an affiliate on each such vesting date. The "Performance Requirement" is tied to the achievement of a specified clinical development activity at the Issuer, which requirement was met as of March 31, 2026. The "Knock-in Requirement" requires that the price of the Issuer's common stock at each applicable vesting date must be equal to or greater than $16.76 per share.